At the ACG meeting, lead investigator Daniel J. Pambianco, MD, will present the abstract “A Phase IIb Study Comparing the Safety and Efficacy of Remimazolam and Midazolam in Colonoscopy.”
The trial compared Remimazolam to Midazolam in 160 colonoscopy patients. The patients either received one of three initial Remimazolam doses or Midazolam followed by “top-ups.” The study compared time to peak sedation, time to full recovery and discharge and safety in the two sedatives.
Researchers found success rates of 92.5 percent to 97.5 percent for the three Remimazolam groups compared to a 75 percent success rate in the Midazolam group. A quarter of the patients in the Midazolam group received propofol as a sedative rescue medication, while only 5 percent of patients in the Remimazolam groups received either propofol or Midazolam.
More articles on gastroenterology:
Is the MD/MBA combination the key to navigating healthcare today?
CRC test ColoMarker receives CE mark
SAGES begins endoscopy safety program
